Articles From: Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor)(R) to Currency Exchange International Announces Election of Directors


LAUSANNE, Switzerland and LEXINGTON, Mass., Oct.
Sign-up for Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor)(R) investment picks
2014/4/7
LAUSANNE, Switzerland and LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, a mTOR inhibitor, in advanced
Sign-up for Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014 investment picks
Designed to target advanced metastatic renal cell carcinoma, the study will determine the maximum tolerated dose of Debio 0932 in combination with everolimus LAUSANNE , Switzerland and LEXINGTON, Massachusetts , October 22, 2013 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS) , an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced the start of an open-label, multicenter Phase I dose-finding study of Debio 0932, a heat shock protein 90 (HSP90) inhibitor in combination with everolimus (Afinitor ® ), an inhibitor of mammalian target of rapamycin (mTOR) in patients with advanced or metastatic renal cell carcinoma (RCC),
Sign-up for Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study with a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor®) investment picks
2014/4/7
Curis Announces Changes to Management Team Canada NewsWire SOURCE Curis Resources Ltd.
Sign-up for Curis Announces Changes to Management Team investment picks
LEXINGTON, Mass., July 25, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced dosing of the first patient in a Phase 1 dose-escalation study of CUDC-427 that is being conducted using a continuous, twice-daily oral dosing regimen in patients with advanced and refractory solid tumors or lymphoma.
Sign-up for Curis Announces Initiation of a Clinical Trial of CUDC-427 In Advanced Malignancies investment picks
2014/3/31
LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that Curis scientists and collaborators will present data from three programs at the Annual Meeting of American Association for Cancer Research (AACR) to be held from April 5 th to 9 th in San Diego, CA.
Sign-up for Curis Announces Presentation of Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting investment picks
2014/3/31
LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND.
Sign-up for Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427 investment picks
LEXINGTON, Mass., July 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the European Commission has granted conditional approval to Erivedge ® (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy.
Sign-up for Curis Announces the Conditional Approval of Erivedge(R) in the European Union investment picks
2014/4/7
CUDC-907 Modulates Expression of Certain Cytokines/ Chemokines, Potentially Targeting Tumor Microenvironment in Addition to Direct Effects on Cancer Cells LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that it reported data from in vitro studies and a translational biomarker analysis for CUDC-907, a dual histone deacytelase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, as well as results from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2014 Annual Meeting.
Sign-up for Curis Reports CUDC-907 and CUDC-427 Data at AACR Annual Meeting 2014 investment picks
2013/12/9
CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity LEXINGTON, Mass., Dec.
Sign-up for Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting investment picks
2014/2/20
LEXINGTON, Mass., Feb.
Sign-up for Curis Reports Fourth Quarter and Year-End 2013 Financial Results investment picks
LEXINGTON, Mass., Aug.
Sign-up for Curis Reports Second Quarter 2013 Financial Results investment picks
2013/11/6
-- CUDC-427 Phase 1 Trial Placed on Partial Clinical Hold by FDA --
Sign-up for Curis Reports Third Quarter 2013 Financial Results and Provides CUDC-427 Development Update investment picks
Curis Resources Ltd.
Sign-up for Curis Resources Ltd. Shareholders Pass All Resolutions At AGM investment picks
2014/4/2
LEXINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 13 th Annual Needham Healthcare Conference at 1:40 p.m. ET on April 9, 2014, in New York City.
Sign-up for Curis to Present at the 13th Annual Needham Healthcare Conference investment picks
LEXINGTON, Mass., Aug.
Sign-up for Curis to Present at the 2013 Wedbush Life Sciences Management Access Conference investment picks
2014/3/4
LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the 26 th Annual ROTH Conference at 8:30 a.m. PT on March 11, 2014, in Laguna Niguel, CA.
Sign-up for Curis to Present at the 26th Annual ROTH Conference investment picks
2014/2/25
LEXINGTON, Mass., Feb.
Sign-up for Curis to Present at the Cowen and Company 34th Annual Health Care Conference investment picks
2014/2/5
LEXINGTON, Mass., Feb.
Sign-up for Curis to Present at the Leerink Global Healthcare Conference investment picks
LEXINGTON, Mass., Dec.
Sign-up for Curis to Present at the Oppenheimer 24th Annual Healthcare Conference investment picks
2014/2/19
LEXINGTON, Mass., Feb.
Sign-up for Curis to Present at the RBC Capital Markets Global Healthcare Conference investment picks
LEXINGTON, Mass., Nov.
Sign-up for Curis to Present at Upcoming Investor Conferences investment picks
2013/9/4
LEXINGTON, Mass., Sept.
Sign-up for Curis to Present at Upcoming Investor Conferences investment picks
2014/2/13
LEXINGTON, Mass., Feb.
Sign-up for Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014 investment picks
2013/7/29
LEXINGTON, Mass., July 29, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS) , an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will release its second quarter financial results on Monday, August 5, 2013, before the market opens.
Sign-up for Curis to Release Second Quarter 2013 Financial Results and Hold Conference Call on August 5, 2013 investment picks
LEXINGTON, Mass., Sept.
Sign-up for Curis to Webcast Investor and Analyst Day in New York City investment picks
2013/8/14
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0892288001&sourceType=1 http://media3.marketwire.com/logos/20120229-cei200.jpg ORLANDO, FLORIDA --
Sign-up for Currency Exchange International Adds Four New Retail Branches investment picks
2014/3/11
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0932705001&sourceType=1 http://media3.marketwire.com/logos/20120229-cei200.jpg TORONTO, ONTARIO --
Sign-up for Currency Exchange International Announces Election of Directors investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Curis and Debiopharm Group(TM) Announce Initiation of Phase I Dose Finding Clinical Study With a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor)(R) to Currency Exchange International Announces Election of Directors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity